Drugs / ALM201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03427073 | Apr 2015 → Mar 2017 | ovarian cancer | Almac Discovery | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALM201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03427073 ↗ |
| Modality | Peptide | “ALM201 is a peptide with anti-angiogenic activity” NCT03427073 ↗ |
| Route | Subcutaneous | “ALM201 administered subcutaneously” NCT03427073 ↗ |